Do analysts rate NCNA or ABVC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NuCana 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 ABVC BioPharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is NCNA or ABVC more profitable?

ABVC BioPharma's return on equity of -62.46% beat NuCana's return on equity. Company Net Margins Return on Equity Return on Assets NuCana N/A -153.61% -116.03% ABVC BioPharma N/A -62.46% -39.99%

Do analysts recommend NCNA or NNVC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NuCana 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 NanoViricides 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Which has better valuation & earnings, NCNA or NNVC?

NanoViricides is trading at a lower price-to-earnings ratio than NuCana, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NuCana N/A N/A -$38.71M -$2.98 N/A NanoViricides N/A N/A -$8.29M -$0.43 N/A

Is NCNA or NNVC more profitable?

NanoViricides' return on equity of -87.90% beat NuCana's return on equity. Company Net Margins Return on Equity Return on Assets NuCana N/A -153.61% -116.03% NanoViricides N/A -87.90% -78.69%

Do analysts recommend NCNA or ALGS?

Aligos Therapeutics has a consensus price target of $38.50, indicating a potential upside of 646.12%. Given Aligos Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Aligos Therapeutics is more favorable than NuCana. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NuCana 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Aligos Therapeutics 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.86

Is NCNA or ALGS more profitable?

NuCana has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -1,919.68%. Aligos Therapeutics' return on equity of -139.47% beat NuCana's return on equity. Company Net Margins Return on Equity Return on Assets NuCana N/A -153.61% -116.03% Aligos Therapeutics -1,919.68% -139.47% -90.88%

Do analysts rate NCNA or LSTA?

Lisata Therapeutics has a consensus price target of $15.00, indicating a potential upside of 315.51%. Given Lisata Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Lisata Therapeutics is more favorable than NuCana. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NuCana 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Lisata Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Is NCNA or LSTA more profitable?

Lisata Therapeutics' return on equity of -103.54% beat NuCana's return on equity. Company Net Margins Return on Equity Return on Assets NuCana N/A -153.61% -116.03% Lisata Therapeutics N/A -103.54% -83.08%

Do analysts rate VIRI or NCNA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Virios Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 NuCana 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, VIRI or NCNA?

Virios Therapeutics is trading at a lower price-to-earnings ratio than NuCana, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Virios Therapeutics N/A N/A -$5.30M -$0.27 N/A NuCana N/A N/A -$38.71M -$2.98 N/A

Is VIRI or NCNA more profitable?

Virios Therapeutics' return on equity of -130.33% beat NuCana's return on equity. Company Net Margins Return on Equity Return on Assets Virios Therapeutics N/A -130.33% -115.00% NuCana N/A -153.61% -116.03%

NuCana (NCNA) Competitors

$1.95 -0.02 (-1.02%)

Closing price 04:00 PM Eastern

Extended Trading

$1.97 +0.02 (+1.18%)

As of 07:03 PM Eastern

Compare

NCNA vs. ABVC, NNVC, ALGS, LSTA, and VIRI

Should you buy NuCana stock or one of its competitors? MarketBeat compares NuCana with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with NuCana include ABVC BioPharma (ABVC), NanoViricides (NNVC), Aligos Therapeutics (ALGS), Lisata Therapeutics (LSTA), and Virios Therapeutics (VIRI). These companies are all part of the "pharmaceutical products" industry.

How does NuCana compare to ABVC BioPharma?

NuCana (NASDAQ:NCNA) and ABVC BioPharma (NASDAQ:ABVC) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, profitability, dividends, analyst recommendations, valuation, institutional ownership and media sentiment.

NuCana has a beta of 2.18, meaning that its share price is 118% more volatile than the broader market. Comparatively, ABVC BioPharma has a beta of 0.56, meaning that its share price is 44% less volatile than the broader market.

In the previous week, ABVC BioPharma had 1 more articles in the media than NuCana. MarketBeat recorded 2 mentions for ABVC BioPharma and 1 mentions for NuCana. NuCana's average media sentiment score of 1.89 beat ABVC BioPharma's score of 1.31 indicating that NuCana is being referred to more favorably in the media.

Company	Overall Sentiment
NuCana	Very Positive
ABVC BioPharma	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NuCana	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ABVC BioPharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

44.0% of NuCana shares are owned by institutional investors. Comparatively, 11.4% of ABVC BioPharma shares are owned by institutional investors. 31.2% of NuCana shares are owned by insiders. Comparatively, 19.0% of ABVC BioPharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

ABVC BioPharma's return on equity of -62.46% beat NuCana's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NuCana	N/A	-153.61%	-116.03%
ABVC BioPharma	N/A	-62.46%	-39.99%

ABVC BioPharma has higher revenue and earnings than NuCana. ABVC BioPharma is trading at a lower price-to-earnings ratio than NuCana, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NuCana	N/A	N/A	-$38.71M	-$2.98	N/A
ABVC BioPharma	$510K	65.76	-$7.91M	-$0.40	N/A

Summary

ABVC BioPharma beats NuCana on 6 of the 11 factors compared between the two stocks.

How does NuCana compare to NanoViricides?

NuCana (NASDAQ:NCNA) and NanoViricides (NYSE:NNVC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, risk, profitability, media sentiment, analyst recommendations, institutional ownership and valuation.

NanoViricides' return on equity of -87.90% beat NuCana's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NuCana	N/A	-153.61%	-116.03%
NanoViricides	N/A	-87.90%	-78.69%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NuCana	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
NanoViricides	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

44.0% of NuCana shares are owned by institutional investors. Comparatively, 10.3% of NanoViricides shares are owned by institutional investors. 31.2% of NuCana shares are owned by company insiders. Comparatively, 3.6% of NanoViricides shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

NuCana has a beta of 2.18, meaning that its stock price is 118% more volatile than the broader market. Comparatively, NanoViricides has a beta of 1.66, meaning that its stock price is 66% more volatile than the broader market.

In the previous week, NuCana had 1 more articles in the media than NanoViricides. MarketBeat recorded 1 mentions for NuCana and 0 mentions for NanoViricides. NuCana's average media sentiment score of 1.89 beat NanoViricides' score of 0.23 indicating that NuCana is being referred to more favorably in the media.

Company	Overall Sentiment
NuCana	Very Positive
NanoViricides	Neutral

NanoViricides is trading at a lower price-to-earnings ratio than NuCana, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NuCana	N/A	N/A	-$38.71M	-$2.98	N/A
NanoViricides	N/A	N/A	-$8.29M	-$0.43	N/A

Summary

NuCana and NanoViricides tied by winning 6 of the 12 factors compared between the two stocks.

How does NuCana compare to Aligos Therapeutics?

NuCana (NASDAQ:NCNA) and Aligos Therapeutics (NASDAQ:ALGS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, valuation, profitability, media sentiment and institutional ownership.

NuCana has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -1,919.68%. Aligos Therapeutics' return on equity of -139.47% beat NuCana's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NuCana	N/A	-153.61%	-116.03%
Aligos Therapeutics	-1,919.68%	-139.47%	-90.88%

44.0% of NuCana shares are held by institutional investors. Comparatively, 60.4% of Aligos Therapeutics shares are held by institutional investors. 31.2% of NuCana shares are held by company insiders. Comparatively, 7.8% of Aligos Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Aligos Therapeutics has higher revenue and earnings than NuCana. NuCana is trading at a lower price-to-earnings ratio than Aligos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NuCana	N/A	N/A	-$38.71M	-$2.98	N/A
Aligos Therapeutics	$2.19M	14.58	-$24.19M	-$8.69	N/A

In the previous week, Aligos Therapeutics had 1 more articles in the media than NuCana. MarketBeat recorded 2 mentions for Aligos Therapeutics and 1 mentions for NuCana. NuCana's average media sentiment score of 1.89 beat Aligos Therapeutics' score of 0.94 indicating that NuCana is being referred to more favorably in the media.

Company	Overall Sentiment
NuCana	Very Positive
Aligos Therapeutics	Positive

Aligos Therapeutics has a consensus price target of $38.50, indicating a potential upside of 646.12%. Given Aligos Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Aligos Therapeutics is more favorable than NuCana.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NuCana	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aligos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

NuCana has a beta of 2.18, suggesting that its share price is 118% more volatile than the broader market. Comparatively, Aligos Therapeutics has a beta of 2.25, suggesting that its share price is 125% more volatile than the broader market.

Summary

Aligos Therapeutics beats NuCana on 12 of the 16 factors compared between the two stocks.

How does NuCana compare to Lisata Therapeutics?

NuCana (NASDAQ:NCNA) and Lisata Therapeutics (NASDAQ:LSTA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, analyst recommendations, dividends, media sentiment, earnings, institutional ownership and valuation.

Lisata Therapeutics' return on equity of -103.54% beat NuCana's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NuCana	N/A	-153.61%	-116.03%
Lisata Therapeutics	N/A	-103.54%	-83.08%

Lisata Therapeutics has a consensus price target of $15.00, indicating a potential upside of 315.51%. Given Lisata Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Lisata Therapeutics is more favorable than NuCana.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NuCana	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Lisata Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

44.0% of NuCana shares are owned by institutional investors. Comparatively, 8.9% of Lisata Therapeutics shares are owned by institutional investors. 31.2% of NuCana shares are owned by company insiders. Comparatively, 9.1% of Lisata Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Lisata Therapeutics has higher revenue and earnings than NuCana. Lisata Therapeutics is trading at a lower price-to-earnings ratio than NuCana, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NuCana	N/A	N/A	-$38.71M	-$2.98	N/A
Lisata Therapeutics	$170K	193.45	-$16.59M	-$1.86	N/A

In the previous week, Lisata Therapeutics had 4 more articles in the media than NuCana. MarketBeat recorded 5 mentions for Lisata Therapeutics and 1 mentions for NuCana. NuCana's average media sentiment score of 1.89 beat Lisata Therapeutics' score of 0.97 indicating that NuCana is being referred to more favorably in the media.

Company	Overall Sentiment
NuCana	Very Positive
Lisata Therapeutics	Positive

NuCana has a beta of 2.18, suggesting that its share price is 118% more volatile than the broader market. Comparatively, Lisata Therapeutics has a beta of 0.81, suggesting that its share price is 19% less volatile than the broader market.

Summary

Lisata Therapeutics beats NuCana on 8 of the 13 factors compared between the two stocks.

How does NuCana compare to Virios Therapeutics?

Virios Therapeutics (NASDAQ:VIRI) and NuCana (NASDAQ:NCNA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, risk, profitability, analyst recommendations, earnings and institutional ownership.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Virios Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
NuCana	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Virios Therapeutics' return on equity of -130.33% beat NuCana's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Virios Therapeutics	N/A	-130.33%	-115.00%
NuCana	N/A	-153.61%	-116.03%

In the previous week, NuCana had 1 more articles in the media than Virios Therapeutics. MarketBeat recorded 1 mentions for NuCana and 0 mentions for Virios Therapeutics. NuCana's average media sentiment score of 1.89 beat Virios Therapeutics' score of 0.00 indicating that NuCana is being referred to more favorably in the news media.

Company	Overall Sentiment
Virios Therapeutics	Neutral
NuCana	Very Positive

Virios Therapeutics is trading at a lower price-to-earnings ratio than NuCana, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Virios Therapeutics	N/A	N/A	-$5.30M	-$0.27	N/A
NuCana	N/A	N/A	-$38.71M	-$2.98	N/A

9.1% of Virios Therapeutics shares are owned by institutional investors. Comparatively, 44.0% of NuCana shares are owned by institutional investors. 12.2% of Virios Therapeutics shares are owned by insiders. Comparatively, 31.2% of NuCana shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Virios Therapeutics has a beta of 1.58, suggesting that its stock price is 58% more volatile than the broader market. Comparatively, NuCana has a beta of 2.18, suggesting that its stock price is 118% more volatile than the broader market.

Summary

NuCana beats Virios Therapeutics on 7 of the 11 factors compared between the two stocks.

Get NuCana News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NCNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NCNA vs. The Competition

Export

Metric	NuCana	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$8.11M	$3.28B	$6.43B	$11.71B
Dividend Yield	N/A	2.33%	2.67%	5.55%
P/E Ratio	-0.65	18.99	24.46	23.62
Price / Sales	N/A	290.48	500.50	105.27
Price / Cash	N/A	118.24	42.36	56.09
Price / Book	0.25	8.00	10.43	6.70
Net Income	-$38.71M	$23.89M	$3.56B	$337.26M
7 Day Performance	-3.94%	-3.49%	-1.39%	-1.41%
1 Month Performance	-7.58%	1.03%	0.86%	1.15%
1 Year Performance	-93.21%	34.39%	19.42%	22.61%

NuCana Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NCNA NuCana	1.4743 of 5 stars	$1.95 -1.0%	N/A	-87.1%	$8.11M	N/A	N/A	30	Positive News
ABVC ABVC BioPharma	1.2853 of 5 stars	$1.44 +12.5%	N/A	-18.5%	$33.28M	N/A	N/A	30	Positive News Gap Up
NNVC NanoViricides	0.3919 of 5 stars	$1.50 -0.7%	N/A	-7.9%	$32.47M	N/A	N/A	20	Gap Down
ALGS Aligos Therapeutics	3.3484 of 5 stars	$5.34 +3.9%	$38.50 +621.0%	-28.5%	$31.81M	$2.19M	N/A	90	News Coverage
LSTA Lisata Therapeutics	2.6395 of 5 stars	$3.37 -3.2%	$15.00 +345.1%	+31.6%	$31.69M	$170K	N/A	30	News Coverage Positive News Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NCNA) was last updated on 6/10/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NuCana (NCNA) Competitors

NCNA vs. ABVC, NNVC, ALGS, LSTA, and VIRI

How does NuCana compare to ABVC BioPharma?

Summary

How does NuCana compare to NanoViricides?

Summary

How does NuCana compare to Aligos Therapeutics?

Summary

How does NuCana compare to Lisata Therapeutics?

Summary

How does NuCana compare to Virios Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NCNA vs. The Competition

NuCana Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NuCana (NCNA) Competitors

NCNA vs. ABVC, NNVC, ALGS, LSTA, and VIRI

How does NuCana compare to ABVC BioPharma?

Which has more risk & volatility, NCNA or ABVC?

Does the media prefer NCNA or ABVC?

Do analysts rate NCNA or ABVC?

Do insiders and institutionals have more ownership in NCNA or ABVC?

Is NCNA or ABVC more profitable?

Which has stronger earnings & valuation, NCNA or ABVC?

Summary

How does NuCana compare to NanoViricides?

Is NCNA or NNVC more profitable?

Do analysts recommend NCNA or NNVC?

Do institutionals & insiders have more ownership in NCNA or NNVC?

Which has more volatility & risk, NCNA or NNVC?

Does the media prefer NCNA or NNVC?

Which has better valuation & earnings, NCNA or NNVC?

Summary

How does NuCana compare to Aligos Therapeutics?

Is NCNA or ALGS more profitable?

Do insiders and institutionals have more ownership in NCNA or ALGS?

Which has stronger valuation & earnings, NCNA or ALGS?

Does the media refer more to NCNA or ALGS?

Do analysts recommend NCNA or ALGS?

Which has more volatility and risk, NCNA or ALGS?

Summary

How does NuCana compare to Lisata Therapeutics?

Is NCNA or LSTA more profitable?

Do analysts rate NCNA or LSTA?

Do institutionals & insiders have more ownership in NCNA or LSTA?

Which has higher valuation & earnings, NCNA or LSTA?

Does the media prefer NCNA or LSTA?

Which has more volatility and risk, NCNA or LSTA?

Summary

How does NuCana compare to Virios Therapeutics?

Do analysts rate VIRI or NCNA?

Is VIRI or NCNA more profitable?

Does the media prefer VIRI or NCNA?

Which has preferable earnings and valuation, VIRI or NCNA?

Do institutionals and insiders have more ownership in VIRI or NCNA?

Which has more risk & volatility, VIRI or NCNA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NCNA vs. The Competition

NuCana Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools